The biopharmaceutical company Shire Announces Launch of Equasym (methylphenidate hydrochloride, modified-release hard capsules), after approval by the Spanish Agency for Medicines and Health Products (AEMP) for the treatment of ADHD.
Sustained release preparations have similar therapeutic effects to immediate release, and they differ from each other by the plasma concentration time profiles during the day, which are reflected in the pharmacodynamic effects. Equasym efficiency is higher in the morning, while other formulations such as Concerta, allow better control of symptoms in the evening. These differences are important when prescribing treatment..
analysis Equasym (Comparison with: Concerta, Medikinet, Strattera y Rubifen)